Latest News and Press Releases

Phase 2 to evaluate safety, tolerability and efficacy of INNA-051 in the prevention of illness due to viral respiratory infectionsStudy to be led by global health physician scientist, Dr. Justin...

Clinical studies demonstrated that INNA-051’s natural defence boosting mechanism is effective in older adultsAdministration of INNA-051 to older adults (65 years old) in a Phase 1 study was...

Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils Approval marks the first new treatment approach for...

Lungpacer Medical Appoints Medical Device and Healthcare Industry Veteran with 20 Years of Experience as CCO

Lungpacer Medical is excited to announce approval of an Investigational Device Exemption (IDE) from the U.S. FDA for the STARI clinical study.

ENA Respiratory Receives US$5m Investment from Flu Lab to Support Clinical Development of Novel Intranasal Antiviral Host Defence Immune Enhancer, INNA-051

Monaghan Medical was named Company of the Year by the Plattsburgh Chamber of Commerce for its contributions to the community and economy.

New York, United States, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Researchers have used peptides to deliver drugs to target cells due to their remarkable efficacy and selectivity towards the different...

Austin, TX, USA, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Acute Respiratory Infection Market Size, Trends and Insights By Drug Type...

aTyr Pharma’s Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting